{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:06:25Z","timestamp":1783523185106,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.radonc.2025.111092","type":"journal-article","created":{"date-parts":[[2025,8,10]],"date-time":"2025-08-10T21:51:24Z","timestamp":1754862684000},"page":"111092","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Does omitting the clinical target volume in stereotactic radiotherapy for NSCLC affect oncologic outcomes? A retrospective analysis"],"prefix":"10.1016","volume":"211","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3951-9275","authenticated-orcid":false,"given":"Philipp","family":"Reinhardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6360-0300","authenticated-orcid":false,"given":"Ilya","family":"Kotov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9914-6728","authenticated-orcid":false,"given":"Daniel","family":"Schmidhalter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1099-9009","authenticated-orcid":false,"given":"Dora","family":"Correia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6996-0646","authenticated-orcid":false,"given":"Olgun","family":"Elicin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5189-0507","authenticated-orcid":false,"given":"Daniel Hendrik","family":"Schanne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.111092_b0005","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.prro.2017.04.014","article-title":"Stereotactic body radiation therapy for early-stage non-small cell lung cancer: executive summary of an ASTRO evidence-based guideline","volume":"7","author":"Videtic","year":"2017","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111092_b0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.radonc.2017.05.012","article-title":"ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer","volume":"124","author":"Guckenberger","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111092_b0015","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jama.2010.261","article-title":"Stereotactic body radiation therapy for inoperable early stage lung cancer","volume":"303","author":"Timmerman","year":"2010","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.radonc.2025.111092_b0020","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.radonc.2010.04.027","article-title":"Dose-response relationship for radiation-induced pneumonitis after pulmonary stereotactic body radiotherapy","volume":"97","author":"Guckenberger","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111092_b0025","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG oncology\/RTOG 0813 trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111092_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2018.02.023","article-title":"ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer","volume":"127","author":"Nestle","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111092_b0035","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.prro.2021.05.006","article-title":"Size and predictive factors of microscopic tumor extension in locally advanced non-small cell lung cancer","volume":"11","author":"Meynard","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111092_b0040","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0360-3016(00)00750-1","article-title":"Evaluation of microscopic tumor extension in non\u2013small-cell lung cancer for three-dimensional conformal radiotherapy planning","volume":"48","author":"Giraud","year":"2000","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111092_b0045","unstructured":"Timmerman RD, Co-Chair R, Fowler J, Choy@utsouthwestern H, Johnstone D, Galvin JM. Radiation Therapy Oncology Group RTOG 0236 A phase II trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with medically inoperable stage I\/II non-small cell lung cancer principal investigator\/radiation oncology; 2004."},{"key":"10.1016\/j.radonc.2025.111092_b0050","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14092318","article-title":"Optimal clinical target volume of radiotherapy based on microscopic extension around the primary gross tumor in non-small-cell lung cancer: a systematic review","volume":"14","author":"Tamaki","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2025.111092_b0055","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1097\/JTO.0b013e318074de34","article-title":"Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study","volume":"2","author":"Onishi","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2025.111092_b0060","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14040933","article-title":"Escalated maximum dose in the planning target volume improves local control in stereotactic body radiation therapy for T1-2 lung cancer","volume":"14","author":"Inagaki","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2025.111092_b0065","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1156389","article-title":"Predicting cancer relapse following lung stereotactic radiotherapy: an external validation study using real-world evidence","volume":"13","author":"Davey","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2025.111092_b0070","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.rpor.2019.01.001","article-title":"Local control rates in stereotactic body radiotherapy (SBRT) of lung metastases associated with the biologically effective dose","volume":"24","author":"Aparicio","year":"2019","journal-title":"Rep Practical Oncol Radiother"},{"key":"10.1016\/j.radonc.2025.111092_b0075","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s00066-020-01687-9","article-title":"Dose coverage impacts local control in ultra-central lung oligometastases treated with stereotactic radiotherapy","volume":"197","author":"Loi","year":"2021","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2025.111092_b0080","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.radonc.2005.09.003","article-title":"Dose-response in stereotactic irradiation of lung tumors","volume":"77","author":"Wulf","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111092_b0085","doi-asserted-by":"crossref","first-page":"558","DOI":"10.4097\/kja.19087","article-title":"Multicollinearity and misleading statistical results","volume":"72","author":"Kim","year":"2019","journal-title":"Korean J Anesthesiol"},{"key":"10.1016\/j.radonc.2025.111092_b0090","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.ijrobp.2023.06.015","article-title":"Declarations of Independence: how embedded multicollinearity errors affect dosimetric and other complex analyses in radiation oncology","volume":"117","author":"Ellsworth","year":"2023","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111092_b0095","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/JTO.0000000000000453","article-title":"Stereotactic ablative radiotherapy for centrally located early stage non\u2013small-cell lung cancer: what we have learned","volume":"10","author":"Chang","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2025.111092_b0100","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1016\/j.ijrobp.2022.07.1494","article-title":"Planning tumor volume and local control following stereotactic body radiation therapy of early-stage NSCLC","volume":"114","author":"Abdelhakiem","year":"2022","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111092_b0105","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1016\/j.prro.2018.09.003","article-title":"Impact of tumor size on local control and pneumonitis after stereotactic body radiation therapy for lung tumors","volume":"9","author":"Parker","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111092_b0110","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ijrobp.2013.08.020","article-title":"The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer","volume":"87","author":"Allibhai","year":"2013","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111092_b0115","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ijrobp.2014.05.055","article-title":"Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis","volume":"90","author":"Zheng","year":"2014","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111092_b0120","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.radonc.2013.01.004","article-title":"Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review","volume":"106","author":"Senthi","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111092_b0125","doi-asserted-by":"crossref","unstructured":"3. Definition of Volumes. J ICRU. 2014;14:55\u201363.","DOI":"10.1093\/jicru_ndx003"},{"key":"10.1016\/j.radonc.2025.111092_b0130","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1309\/P47FYW5U4CRQ0WFE","article-title":"Wedge resection margin distances and residual adenocarcinoma in lobectomy specimens","volume":"120","author":"Goldstein","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.radonc.2025.111092_b0135","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ijrobp.2007.03.023","article-title":"Clinicopathologic analysis of microscopic extension in lung adenocarcinoma: defining clinical target volume for radiotherapy","volume":"69","author":"Grills","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111092_b0140","doi-asserted-by":"crossref","unstructured":"Schmitt M, Aussenac L, Seitlinger J, Lindner V, No\u00ebl G, Antoni D. Evaluation of microscopic tumour extension in localized stage non-small-cell lung cancer for stereotactic radiotherapy planning. Cancers 2022;14:1282.","DOI":"10.3390\/cancers14051282"},{"key":"10.1016\/j.radonc.2025.111092_b0145","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ijrobp.2007.04.065","article-title":"Feasibility of pathology-correlated lung imaging for accurate target definition of lung tumors","volume":"69","author":"Stroom","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111092_b0150","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijrobp.2008.06.1939","article-title":"Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation","volume":"74","author":"Guckenberger","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111092_b0155","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.radonc.2013.08.028","article-title":"Microscopic disease extensions as a risk factor for loco-regional recurrence of NSCLC after SBRT","volume":"109","author":"Salguero","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111092_b0160","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.prro.2015.09.012","article-title":"Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree","volume":"6","author":"Haseltine","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111092_b0165","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.jtho.2019.04.018","article-title":"Safety and effectiveness of stereotactic ablative radiotherapy for ultra-central lung lesions: a systematic review","volume":"14","author":"Chen","year":"2019","journal-title":"J Thoracic Oncol"},{"key":"10.1016\/j.radonc.2025.111092_b0170","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.ijrobp.2016.03.024","article-title":"Simple factors associated with radiation-induced lung toxicity after stereotactic body radiation therapy of the thorax: a pooled analysis of 88 studies","volume":"95","author":"Zhao","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111092_b0175","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3390\/cancers7020820","article-title":"Complications from stereotactic body radiotherapy for lung cancer","volume":"7","author":"Kang","year":"2015","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2025.111092_b0180","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ijrobp.2010.08.056","article-title":"A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy","volume":"82","author":"Barriger","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111092_b0185","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.radonc.2007.09.004","volume":"85","author":"Jin","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111092_b0190","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijrobp.2024.07.2332","article-title":"Measuring the integration of stereotactic ablative radiotherapy plus surgery for early-stage non-small cell lung cancer: long-term clinical outcomes","volume":"121","author":"Tan","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025045967?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025045967?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T20:03:12Z","timestamp":1759521792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025045967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":38,"alternative-id":["S0167814025045967"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111092","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does omitting the clinical target volume in stereotactic radiotherapy for NSCLC affect oncologic outcomes? A retrospective analysis","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111092","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111092"}}